Does Medicaid Cover Zepbound? The State-by-State Patchwork

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Medicaid AOM coverage is a state choice; federal law makes it optional, not mandatory
• Approximately 14 states and DC cover Zepbound for weight loss as of May 2026
• The December 2024 FDA OSA approval opens a coverage path that may apply even in states without weight-loss coverage
• Medicaid copays are very low ($0-$4) where coverage exists, making it more accessible than commercial plans when available
• States without coverage have very limited appeal paths; the realistic alternatives are Lilly Direct or compounded tirzepatide

Direct answer

Whether Medicaid covers Zepbound depends entirely on your state. Federal Medicaid law (Social Security Act §1927) lists weight-loss agents as optional coverage, leaving the decision to each state. As of May 2026, approximately 14 states and the District of Columbia cover Zepbound for weight loss with prior authorization. The remaining states either exclude AOMs entirely or limit coverage to specific clinical scenarios. The December 2024 FDA approval of Zepbound for obstructive sleep apnea created an additional coverage path that may apply across more states because OSA treatment is generally a covered service. Medicaid copays where coverage exists are very low (typically $0 to $4 per fill), making access genuinely affordable for qualifying patients.

Table of contents

1. How Medicaid drug coverage is structured
2. The states that cover Zepbound
3. The states that exclude it
4. PA criteria in covering states
5. The OSA pathway under state Medicaid
6. Costs under Medicaid
7. Dual-eligible beneficiaries
8. Coverage exception requests
9. Alternatives when state Medicaid says no
10. FAQ
11. Sources

How Medicaid drug coverage is structured

Medicaid is a federal-state partnership. The federal Medicaid statute requires states to cover certain mandatory drug categories and permits states to add optional categories. Anti-obesity medications fall in the optional bucket under §1927(d)(2)(A) of the Social Security Act.

Each state runs a Medicaid agency that maintains a Preferred Drug List (PDL). The PDL identifies which medications the state covers and under what conditions. Most states contract with managed-care organizations (MCOs) to administer Medicaid benefits; the MCOs follow the state's PDL while operating their own PA processes.

When you ask "does Medicaid cover Zepbound," the actual question is: "Does my state's Medicaid PDL include Zepbound, and what does my MCO require for PA?"

The states that cover Zepbound

As of May 2026, states with confirmed Medicaid coverage of Zepbound for weight loss (with PA):

• California (Medi-Cal): covers with strict PA, BMI ≥ 30, prior lifestyle intervention
• Pennsylvania: covers with PA, comorbidity requirements common
• Michigan: covers with PA after 2024 expansion
• North Carolina: covers with PA, prior intervention documentation required
• Virginia: covers with PA on PDL
• Massachusetts (MassHealth): covers with PA
• Minnesota: covers with PA
• Connecticut (HUSKY Health): covers with PA
• Delaware: covers with PA
• Rhode Island: covers with PA
• New Hampshire: covers with PA
• Maryland: covers with PA
• New Mexico: covers with PA
• District of Columbia: covers with PA

This list shifts. Several states added coverage during 2024-2025 budget cycles. Others have proposed adding coverage in 2026 budgets currently pending. Verify with your state's published PDL before relying on this list.

The states that exclude it

The majority of states do not cover Zepbound for weight loss on Medicaid. The most common patterns:

• Full AOM exclusion: Texas, Florida, Georgia, Tennessee, Arizona, and others. Mounjaro for T2D is covered; Zepbound for weight loss is not.
• T2D-only path: Most non-covering states will cover Mounjaro for T2D under standard Medicaid PA rules, but Zepbound for weight loss is excluded.
• Children-only or pregnancy-only AOM coverage: A few states cover AOMs only for narrowly-defined populations (rare and shifting).

State budget pressure is the dominant reason for non-coverage. State Medicaid programs share costs with the federal government (federal match rate varies by state, generally 50-83%), but states still face significant marginal cost for expanded coverage.

PA criteria in covering states

Typical PA elements in states that cover Zepbound:

• BMI ≥ 30, or BMI ≥ 27 with at least one obesity-related comorbidity
• Age ≥ 18 (some states have separate criteria for adolescents)
• Documentation of prior weight-management intervention for at least 6 months
• Prescriber attestation of continued lifestyle counseling alongside medication
• No concurrent GLP-1 use
• Reauthorization: ≥ 5% baseline weight loss at 6 months

Some states add step therapy (phentermine or Saxenda first). Some require participation in a state-supported weight-management program. California's Medi-Cal program, for example, requires evidence of participation in a clinically supervised weight-management program prior to AOM approval.

The OSA pathway under state Medicaid

Federal Medicaid law requires states to cover drugs for medically-accepted indications. The December 2024 FDA approval of Zepbound for OSA created a covered indication that does not depend on the AOM coverage choice.

State Medicaid programs began updating PDLs in 2025 to include Zepbound for OSA. The PA requirements are similar to Medicare's:

• Sleep study (in-lab or home) showing AHI ≥ 15 events/hour
• BMI ≥ 30
• ICD-10 G47.33 on the prescription
• Trial of CPAP or documented contraindication (varies by state)

The OSA pathway is especially significant for Medicaid beneficiaries in states without weight-loss AOM coverage. A patient in Texas Medicaid who has documented OSA and BMI ≥ 30 may have a covered path to Zepbound that did not exist before December 2024.

Costs under Medicaid

Medicaid drug copays are statutorily limited. Adult copays generally range from $0 to $4 per prescription. Specific rates by state and category:

State Medicaid	Typical adult copay for Tier 3 drug
California Medi-Cal	$1 per prescription
Pennsylvania	$3 per prescription
Michigan	$3 per prescription
Massachusetts MassHealth	$3.65 per prescription (most categories)
North Carolina	$3 per prescription
Children's Health Insurance Program (CHIP)	$0 to $2

These figures reflect what the beneficiary pays at the pharmacy counter. The Medicaid program itself pays significantly more per fill ($600-$900 net of rebates negotiated under the Medicaid Drug Rebate Program, which receives the deepest manufacturer discounts of any payer).

Dual-eligible beneficiaries

Medicare-Medicaid dual-eligibles have a specific coverage hierarchy for prescriptions:

1. Medicare Part D is the primary prescription benefit
2. Medicare's weight-loss exclusion applies to Zepbound prescriptions for weight loss
3. Medicaid does not generally provide wrap-around AOM coverage for dual-eligibles even in states with AOM benefits
4. The OSA pathway through Medicare Part D is the most viable covered route for dual-eligibles
5. Extra Help (Low Income Subsidy) reduces Part D copays for qualifying beneficiaries

Coverage exception requests

Medicaid coverage exception requests work differently than commercial appeals. The structure varies by state:

• Some states use "non-preferred drug" exception requests; the prescriber demonstrates medical necessity
• Some states allow "fair hearing" requests if a benefit is denied
• Time limits vary; check your state Medicaid agency's published procedures
• Approval rates are generally lower for non-formulary drugs than for commercial plans

For OSA-indicated prescriptions in states with otherwise-excluded weight-loss coverage, the exception request strategy is to frame the prescription clearly under the OSA indication with sleep-study documentation. State PDL listings for Zepbound under OSA have been added at different rates; some states cover it explicitly, others require exception requests.

Alternatives when state Medicaid says no

For Medicaid beneficiaries in non-covering states with no OSA pathway:

• Lilly Direct ($499/mo): Available as a cash-pay option. The cost is significant for Medicaid-eligible budgets but is FDA-approved Zepbound.
• Compounded tirzepatide ($199-$399/mo): Through a 503A pharmacy. Not FDA-approved. Not equivalent to Zepbound.
• Patient assistance programs: Eli Lilly offers a patient assistance program for uninsured patients meeting income criteria. Medicaid beneficiaries are generally excluded from the PAP because they have other coverage.
• Clinical trials: Tirzepatide and related compounds are in ongoing trials; clinicaltrials.gov lists current studies.

The honest assessment: patients on Medicaid in non-covering states face the most constrained choices among all coverage categories. The OSA pathway is the most reliable covered alternative when clinical criteria are met. Without OSA, self-pay options are expensive relative to typical Medicaid copays.

Contrary view: should state Medicaid cover Zepbound?

State Medicaid budgets are zero-sum. Adding AOM coverage means either raising state taxes, reducing other Medicaid benefits, or accepting higher federal-state cost-sharing pressure. The argument against state AOM coverage isn't ignorance; it's resource allocation.

Three substantive concerns from non-covering states' perspective:

• Medicaid populations have high rates of obesity but also limited resources for adherence support (transportation to monthly visits, refrigeration for injections, time for follow-up visits)
• Real-world GLP-1 discontinuation rates among lower-income patients run higher than in clinical trials (sometimes exceeding 70% at 12 months in published Medicaid claims data)
• State Medicaid programs serve children, pregnant women, disabled adults, and elderly beneficiaries with conditions where evidence is stronger and budget impact more manageable

The case for coverage: obesity is a chronic disease with severe complications, GLP-1 medications produce clinically significant outcomes, and excluding coverage perpetuates health-equity gaps. Both arguments are defensible. The patient question is how to operate within the system as it exists.

Decision framework

If you're on Medicaid and your state covers Zepbound: Work with your prescriber to submit complete PA documentation. Copays are minimal once PA clears.

If your state doesn't cover for weight loss but you have OSA: Request coverage under the OSA indication with sleep-study documentation.

If your state doesn't cover and you don't have OSA: Compare Lilly Direct ($499/mo) vs compounded tirzepatide ($199-$399/mo). Both are out-of-pocket.

If you're dual-eligible: Medicare Part D rules govern. The OSA pathway is the strongest covered option.

FAQ

Does Medicaid cover Zepbound? Depends on your state. Roughly 14 states and DC cover for weight loss; most states do not.

Which states cover it? California, Pennsylvania, Michigan, North Carolina, Virginia, Massachusetts, Minnesota, Connecticut, Delaware, Rhode Island, New Hampshire, Maryland, New Mexico, DC, and others. Verify with your state PDL.

Why isn't it covered everywhere? Federal law makes AOM coverage optional. States choose based on budget priorities.

What does Zepbound cost on Medicaid? $0-$4 per fill where covered. Very low compared to commercial plans.

Does Medicaid cover Zepbound for OSA? Most states began covering for OSA after the December 2024 FDA approval. Requires sleep-study documentation.

Can I appeal a Medicaid denial? Yes, through your state's coverage-exception or fair-hearing process. Approval rates for non-formulary drugs are generally lower than for commercial appeals.

What if I'm dual-eligible? Medicare Part D is primary. Weight-loss exclusion applies; OSA pathway is the strongest covered route.

Does Medicaid cover compounded tirzepatide? No. Compounded medications are not FDA-approved and are not on Medicaid PDLs.

Sources

1. Social Security Act §1927(d)(2). Medicaid prescription drug coverage exclusions and options.
2. Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program guidance. Updated 2025.
3. Kaiser Family Foundation. State-by-state Medicaid AOM coverage tracker. 2026 edition.
4. Jastreboff AM et al. Tirzepatide Once Weekly for Treatment of Obesity. NEJM. 2022.
5. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea and Obesity. NEJM. 2024.
6. FDA. Zepbound prescribing information. Updated 2024.
7. California Medi-Cal Pharmacy Benefits. Anti-obesity medication PA criteria. 2026.
8. Pennsylvania Medical Assistance Pharmacy Program. Preferred Drug List. 2026.
9. Massachusetts MassHealth Drug List. 2026.
10. Eli Lilly. LillyDirect self-pay program. Accessed May 2026.
11. The Obesity Society. State Medicaid AOM coverage advocacy report. 2024.
12. Government Accountability Office. Medicaid coverage of weight-loss medications. 2024 report.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information about Medicaid coverage policies. We do not enroll patients in Medicaid, file Medicaid claims, or provide benefits counseling. State Medicaid rules vary; consult your state Medicaid agency or Medicaid managed-care plan for binding coverage determinations.

Compounded Medication Notice. Compounded tirzepatide prepared by 503A pharmacies is not FDA-approved and is not therapeutically equivalent to Zepbound. State Medicaid programs do not include compounded medications on Preferred Drug Lists.

Results Disclaimer. State Medicaid coverage policies change with state budget cycles. The state list and cost figures here reflect publicly available PDL information as of the writing date. Verify current status directly with your state Medicaid agency.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medi-Cal, MassHealth, HUSKY Health, and other named state programs are operated by their respective state governments. FormBlends has no affiliation with any state Medicaid program or with the federal Centers for Medicare and Medicaid Services.